Announcements / News | ||
Summary Statement Information |
---|
Shown in the summary statement are a priority score
and a percentile ranking, if applicable. For
the most part, only R01 and R21applications receive a percentile ranking. The priority score is determined by
averaging the scores given individually and privately by each voting member of
the study section. The priority score
scale ranges from 100 to 500, with 100 representing the highest scientific
merit. The percentile ranking
reflects the relative standing of your application among all those evaluated by
the study section for this and the previous two meetings. All scored applications will also
be forwarded to the
next meeting of
the National Cancer Advisory Board (NCAB) (http://deainfo.nci.nih.gov/advisory/ncab.htm). If your application is selected for funding, you will
be contacted by NCI staff. The dollar
level of the award may be reduced from the study section's recommended direct
costs as a result of fiscal constraints within the NCI or further staff
evaluation. If your application is
not selected for funding, you will not be formally
notified. However, you can contact your Program Director at any
time with questions about your summary statement or to discuss options
that may be available to you. Your
Program Director's name, phone number, and email address are located in the
upper left hand corner of the first page of the summary statement. Any official review
appeals must be filed no later than 30 calendar days following the above
NCAB meeting. The Division of
Cancer Biology is dedicated to providing a high level of program support to the
scientific community. Should you feel
the need for recourse, you are welcome to contact the Division Ombudsman, Dr.
Dan Gallahan, by telephone at (301) 496-8636 or e-mail at dg13w@nih.gov. |